Compound News and Research

RSS

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced 10 new or updated software packages to help customers harness the power of its new-generation liquid chromatography-mass spectrometry (LC-MS) instruments and turn data into knowledge in a wide range of discovery and quantitation experiments.

From Thermo Fisher Scientific Inc. 10 Jun 2013

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Thermo Scientific Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system, combining its three mass analyzers –quadrupole, Orbitrap and linear ion trap – in a novel “Tribrid” architecture that offers unprecedented depth of analysis of complex biological samples.

From Thermo Fisher Scientific Inc. 10 Jun 2013

New analytical techniques show certain foodstuffs exceed permitted levels of mycotoxins

Researchers from the University of Granada (Spain) have analysed the presence of patulin, a type of toxin produced by fungi, in several commercial apple juices. The results show that more than 50% of the samples analysed exceed the maximum limits laid down by law.

10 Jun 2013

Cancer cells' appetite for sugar may have serious consequences for immune cell function

Cancer cells' appetite for sugar may have serious consequences for immune cell function, researchers at Washington University School of Medicine in St. Louis have learned.

7 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.

6 Jun 2013

Scientists suggest that Oprl1 receptor is altered in mice with PTSD-like symptoms

When injected into mice immediately following a traumatic event, a new drug prevents the animals from developing memory problems and increased anxiety that are indicative of post-traumatic stress disorder.

6 Jun 2013

Scientists develop first dual-action drug against melanoma skin cancer cells

Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology.

6 Jun 2013

New plug-in optical sensor can help diagnose Kaposi's sarcoma

As antiretroviral drugs that treat HIV have become more commonplace, the incidence of Kaposi's sarcoma, a type of cancer linked to AIDS, has decreased in the United States.

5 Jun 2013

Study reveals connection between impaired hGH levels, sleep fragmentation

If you've heard that Growth Hormone therapy can reduce wrinkles, tighten saggy skin, decrease body fat, increase lean muscle mass, boost energy, rev up sex drive, and make you look and feel decades — not years, but DECADES — younger, you can now add one more ostensible benefit to the list… a good night's sleep!

5 Jun 2013

Review on new, hazardous drugs of abuse presented in Journal of Addiction Medicine

The last few years have seen the emergence of a new drug problem in so-called "bath salts"-actually "designer stimulants," packaged and sold in ways that skirt drug laws. A review and update on these designer drugs is presented in the June Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine.

5 Jun 2013

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

4 Jun 2013

Discovery could reveal potential new drug options for malaria treatment

Malaria parasites that develop resistance to the most effective class of anti-malarial drugs may become susceptible to other treatments as a result. The discovery could reveal potential new drug options, which would be essential in the event of resistance to the best anti-malarials.

4 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

Spicing up fingerprints

It is most commonly used to spice up Indian cuisine, but scientists at Sheffield Hallam University have discovered turmeric could be used to help solve crimes.

From Sheffield Hallam University 3 Jun 2013

Nearly 2/3 of solid tumors carry at least one mutation that may be targeted by existing compound

Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3.

1 Jun 2013

New therapy for lung cancer produces manageable side effects

A promising new therapy for the most common form of lung cancer appears to produce largely manageable side effects, and an ongoing clinical trial is determining whether the compound treats tumors more effectively than what's on the market, according research that scientists at Fox Chase Cancer Center will present at the 49th Annual Meeting of the American Society of Clinical Oncology on Saturday, June 1.

1 Jun 2013

New drug for multiple myeloma could be available within next few months in Europe

The International Myeloma Foundation - improving the quality of life of myeloma patients while working toward prevention and a cure - today said the newest drug for treating multiple myeloma could be available to patients in Europe within the next few months.

1 Jun 2013

Fujikura, Micro-Imaging Solutions to jointly co-market CMOS-based endoscopes

Fujikura Ltd and Micro-Imaging Solutions announced that they have entered into a license agreement to jointly co-market nano-sized, complementary metal-oxide semiconductor, or CMOS, based endoscopes.

1 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

Compound News and Research

New LC-MS software to transform high performance mass spectrometry unveiled by Thermo Fisher Scientific

World’s first “Tribrid” LC-MS launched by Thermo Fisher Scientific

New analytical techniques show certain foodstuffs exceed permitted levels of mycotoxins

Cancer cells' appetite for sugar may have serious consequences for immune cell function

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

RXi Pharmaceuticals reports positive results from 2 placebo-controlled double blind studies of RXI-109

Scientists suggest that Oprl1 receptor is altered in mice with PTSD-like symptoms

Scientists develop first dual-action drug against melanoma skin cancer cells

New plug-in optical sensor can help diagnose Kaposi's sarcoma

Study reveals connection between impaired hGH levels, sleep fragmentation

Review on new, hazardous drugs of abuse presented in Journal of Addiction Medicine

Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Discovery could reveal potential new drug options for malaria treatment

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

Spicing up fingerprints

Nearly 2/3 of solid tumors carry at least one mutation that may be targeted by existing compound

New therapy for lung cancer produces manageable side effects

New drug for multiple myeloma could be available within next few months in Europe

Fujikura, Micro-Imaging Solutions to jointly co-market CMOS-based endoscopes

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News